Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-steroidal agent

Stefano Veraldi, Paolo De Micheli, Rossana Schianchi, Luisa Lunardon

Research output: Contribution to journalArticle

Abstract

Atopiclair® (Zarzenda®) is a topical non-steroidal anti-inflammatory agent for the treatment of allergic diseases of the skin. Three main ingredients are contained in this product: glycyrrhetinic acid, telmesteine and Vitis vinifera extracts. Other ingredients include: allantoin, α-bisabolol, capryloyl glycine, hyaluronic acid, shea butter and tocopheryl acetate. Two previous randomized, double-blind, vehicle-controlled clinical studies provided evidence that Atopiclair is effective in the treatment of atopic dermatitis. This article presents an open, multicenter, sponsor-free, study on the anti-pruritic activity of this product in adult patients with mild-to-moderate atopic dermatitis. The Median Visual Analogue Scale (VAS) values were: at the start of the study (T0), median VAS was 48.5 mm; three weeks later (T1), median VAS was 34.1 mm (-14.4 mm from baseline); six weeks later (T2), median VAS was 24.6 mm (-23.9 mm from baseline). Statistical analysis revealed that differences between T0 versus T1, T0 versus T2 and T1 versus T2 were highly significant (p

Original languageEnglish
Pages (from-to)537-539
Number of pages3
JournalJournal of drugs in dermatology : JDD
Volume8
Issue number6
Publication statusPublished - Jun 2009

    Fingerprint

ASJC Scopus subject areas

  • Dermatology

Cite this